Cargando…

Useful pharmacodynamic endpoints in children: selection, measurement, and next steps

Pharmacodynamic (PD) endpoints are essential for establishing the benefit-to-risk ratio for therapeutic interventions in children and neonates. This article discusses the selection of an appropriate measure of response, the PD endpoint, which is a critical methodological step in designing pediatric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, Lauren E, Sinha, Yashwant, Barker, Charlotte I S, Standing, Joseph F, Offringa, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023695/ https://www.ncbi.nlm.nih.gov/pubmed/29667952 http://dx.doi.org/10.1038/pr.2018.38

Ejemplares similares

Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
por: Germovsek, Eva, et al.
Publicado: (2018)

Pharmacokinetic studies in children: recommendations for practice and research
por: Barker, Charlotte I S, et al.
Publicado: (2018)

Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
por: Germovsek, Eva, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology()
por: Barker, Charlotte I.S., et al.
Publicado: (2014)

Discuss Next Steps
por: Jaffray, David, et al.
Publicado: (2017)

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
por: Ang, Joo Ern, et al.
Publicado: (2012)

Next steps
por: Gasthuber, Martin
Publicado: (2017)

A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
por: Bever, Katherine M., et al.
Publicado: (2021)

Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases
por: Pan, Shan, et al.
Publicado: (2019)

Factorization at Next-to-Leading Power and Endpoint Divergences in $gg\to h$ Production
por: Liu, Ze Long, et al.
Publicado: (2022)

Study of methods for endpoint aware inspection in a next generation firewall
por: Heino, Jenny, et al.
Publicado: (2022)

What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies
por: Picetti, Roberto, et al.
Publicado: (2019)

Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages
por: Voak, Andrew A, et al.
Publicado: (2018)

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
por: Germovsek, Eva, et al.
Publicado: (2016)

Next steps
por: Chierici, Andrea
Publicado: (2018)

The next steps
por: Rada, Juan, et al.
Publicado: (2004)

The next steps
por: Jankharia, Bhavin
Publicado: (2008)

The next step
por: Rimmer, Elsie Margaret, et al.
Publicado: (1993)

The Next Steps
Publicado: (1959)

The Next Step
Publicado: (1924)

The Next Step
Publicado: (1919)

Target Engagement Analysis and Link to Pharmacodynamic Endpoint for a Novel Class of CNS-penetrant and Efficacious p38α MAPK Inhibitors
por: Bachstetter, Adam D., et al.
Publicado: (2014)

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma
por: Campbell, Belinda A., et al.
Publicado: (2020)

Digital mental health: challenges and next steps
por: Smith, Katharine A, et al.
Publicado: (2023)

Next Steps for Interventions Targeting Adolescent Dietary Behaviour
por: Evans, Charlotte E. L.
Publicado: (2020)

Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii
por: Phee, Lynette M, et al.
Publicado: (2019)

Mortality in schizophrenia: a measurable clinical endpoint
por: Bushe, Chris J, et al.
Publicado: (2010)

Precision mass measurements utilizing beta endpoints
por: Moltz, D M, et al.
Publicado: (1981)

Importance of achieving the composite endpoints in diabetes
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2013)

Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials
por: Muir, Keith W., et al.
Publicado: (2016)

Discussion and next steps
por: CERN. Geneva
Publicado: (2014)

MPLS: next steps
por: Davie, Bruce S, et al.
Publicado: (2008)

OCM - next steps?
por: Moscicki, Jakub
Publicado: (2022)

The Next Step at the "London"
Publicado: (1921)

The Next Steps…for IJEM
por: Chowdhury, Subhankar
Publicado: (2017)

Patients’ preferences for selection of endpoints in cardiovascular clinical trials
por: Chow, Robert D., et al.
Publicado: (2014)

Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints
por: Blussé van Oud-Alblas, Heleen J., et al.
Publicado: (2019)

Wheeze is an unreliable endpoint for bronchial methacholine challenges in preschool children
por: Stewart, Lora, et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of dobutamine in neonates on the first days of life
por: Hallik, Maarja, et al.
Publicado: (2020)

Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models
por: Truong, Van Thuy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4320is2n93u0sb5o52inc0bp3f